SHP.L - Shire plc

LSE - LSE Delayed Price. Currency in GBp
3,822.50
-152.50 (-3.84%)
As of 9:25AM BST. Market open.
Stock chart is not supported by your current browser
Previous Close3,975.00
Open3,800.00
Bid3,822.50 x 51000
Ask3,824.00 x 53800
Day's Range3,800.00 - 3,858.00
52 Week Range2,940.50 - 5,021.00
Volume920,911
Avg. Volume4,181,501
Market Cap34.583B
Beta1.27
PE Ratio (TTM)8.17
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.25 (0.71%)
Ex-Dividend Date2018-03-08
1y Target EstN/A
  • MarketWatch8 minutes ago

    FTSE 100 rises, as pound falls on BOE rate-hike doubts

    Shire falls as Allergan rules out bidGovernor of the Bank of England Mark Carney. U.K. stocks advanced Friday, aided by a drop in the pound’s value after Bank of England Governor Mark Carney suggested that an interest-rate increase may not come next month as expected. The FTSE 100 index (^FTSE) was up 0.4% to 7,354.50, led higher by the financial group, while the health care sector was in the red.

  • Financial Times51 minutes ago

    [$$] Shire shares down 3.7% after Allergan rules out bid

    Allergan had made it known that it had contemplated an offer but then decided against it, which sent Shire’s share price down at 3,823 pence from yesterday’s close at 3,831 pence. Takeda shares fell by 4.67 per cent. Shire on Friday confirmed that Allergan had backed away.

  • Japan's Takeda shares drop as investors fret over Shire pursuit
    Reuters2 hours ago

    Japan's Takeda shares drop as investors fret over Shire pursuit

    Takeda Pharmaceutical Co Ltd shares lost almost 5 percent of their value on Friday as investors fretted over the size of any deal the Japanese firm would have to make to seal its record-breaking purchase of London-listed Shire PLC. Shire late on Thursday said it had rejected Takeda's $63 billion cash-and-stock conditional offer, saying the offer - and two previous offers - significantly undervalued its growth prospects and drugs in development. Several analysts said Takeda, Japan's biggest drugmaker by sales, will need to substantially raise the cash component of its offer make it attractive to Shire shareholders.

  • Reuters2 hours ago

    Japan's Takeda shares drop as investors fret over Shire pursuit

    Takeda Pharmaceutical Co Ltd shares lost almost 5 percent of their value on Friday as investors fretted over the size of any deal the Japanese firm would have to make to seal its record-breaking purchase of London-listed Shire PLC (SHP.L). Shire late on Thursday said it had rejected Takeda's $63 billion (£44.8 billion) cash-and-stock conditional offer, saying the offer - and two previous offers - significantly undervalued its growth prospects and drugs in development. Several analysts said Takeda, Japan's biggest drugmaker by sales, will need to substantially raise the cash component of its offer make it attractive to Shire shareholders.

  • Shire Rebuff May Not Dim Takeda's Appetite for $60 Billion Deal
    Bloomberg3 hours ago

    Shire Rebuff May Not Dim Takeda's Appetite for $60 Billion Deal

    Three years ago, Christophe Weber made waves in Japan when 237-year-old Japanese drugmaker Takeda Pharmaceutical Co. named him its first foreign chief. These days, he’s in the hot seat for his controversial ...

  • The Wall Street Journal4 hours ago

    [$$] Fast-Growing Shire Had Pharmaceutical Rivals in a Takeover Frenzy

    Drugmaker Shire rebuffed a takeover bid from rival Takeda Pharmaceutical, then Allergan took a look.

  • The Wall Street Journal4 hours ago

    [$$] Third Time Unlucky for Takeda and Shire

    Shire has rejected Takeda’s three offers to buy it, and there may not be much more wiggle room to sweeten the bid.

  • Shire to World: Let the Bidding Begin
    Motley Fool6 hours ago

    Shire to World: Let the Bidding Begin

    Takeda's made three offers to acquire Shire in the past month. Now a new bidder is emerging for the U.K. biopharma.

  • Reuters8 hours ago

    PRESS DIGEST- Financial Times - April 20

    - Brunswick founder Alan Parker resigned as chair of Save the Children after current and former employees criticised his handling of sexual harassment at the charity. - Shire Plc rejected a 42.4 billion pound takeover offer from Japanese rival Takeda Pharmaceutical Co Ltd and Botox-maker Allergan Plc disclosed it had considered a run at the company but said it "does not intend to make an offer for Shire".

  • Reuters8 hours ago

    PRESS DIGEST- Financial Times - April 20

    - Brunswick founder Alan Parker resigned as chair of Save the Children after current and former employees criticised his handling of sexual harassment at the charity. - Shire Plc rejected a 42.4 billion pound takeover offer from Japanese rival Takeda Pharmaceutical Co Ltd and Botox-maker Allergan Plc disclosed it had considered a run at the company but said it "does not intend to make an offer for Shire".

  • Reuters9 hours ago

    PRESS DIGEST- British Business - April 20

    The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times Ultra Electronics Holdings Plc has ...

  • Reuters11 hours ago

    Shire rejects $63 billion Takeda bid as Allergan drops pursuit

    NEW YORK/LONDON (Reuters) - Rare disease drug maker Shire Plc (SHP.L) said on Thursday it had rejected a $63 billion (44.7 billion pounds) cash-and-stock acquisition offer by Japan's Takeda Pharmaceutical Co Ltd , while Allergan Plc (AGN.N) reversed course on pursuing a rival bid. An acquisition of Shire by Takeda would be by far the biggest acquisition of a drug company year-to-date. Botox-maker Allergan confirmed on Thursday it was considering an offer for Shire after Reuters reported on its interest, sending its shares down 7 percent.

  • Allergan Bows Out Of Shire Battle Against Takeda After Stock Slammed
    Investor's Business Daily12 hours ago

    Allergan Bows Out Of Shire Battle Against Takeda After Stock Slammed

    In a rapid turnaround, Allergan said late Thursday it doesn't intend to bid on Shire — leaving thrice-rebuffed Takeda Pharmaceuticals alone in the race for the rare disease drugmaker.

  • Why Is Allergan (AGN) Stock Falling Today?
    Zacks13 hours ago

    Why Is Allergan (AGN) Stock Falling Today?

    Allergan (AGN) shares have fallen 5.8% on the day, while Shire plc (SHPG) is up 3.4% so far. These fluctuations come in light of a $50 billion dollar acquisition deal for Shire that is now taking a competitive turn.

  • Is Shire plc’s (NASDAQ:SHPG) PE Ratio A Signal To Buy For Investors?
    Simply Wall St.14 hours ago

    Is Shire plc’s (NASDAQ:SHPG) PE Ratio A Signal To Buy For Investors?

    Shire plc (NASDAQ:SHPG) is trading with a trailing P/E of 12.1x, which is lower than the industry average of 27.3x. While this makes SHPG appear like a great stock toRead More...

  • MarketWatch14 hours ago

    Blink and you missed it: Allergan doesn't plan to make a Shire bid

    Capping a day of high acquisition drama, Allergan PLC has said it does not plan to make a bid for drugmaker Shire -- mere hours after saying it was considering such a bid. A play for Shire would have pitted Allergan against drugmaker Takeda Pharmaceutical Co. Ltd. , which had its about $60 billion bid for Shire rejected but has continued negotiations. Many Wall Street analysts viewed the potential Allergan-Shire deal poorly.

  • Japanese giant Takeda faces uphill battle to buy drug maker Shire after £42bn bid rejected
    The Telegraph14 hours ago

    Japanese giant Takeda faces uphill battle to buy drug maker Shire after £42bn bid rejected

    Japanese giant Takeda faces uphill battle to buy drug maker Shire after £42bn bid rejected

  • Benzinga15 hours ago

    CNBC: Allergan-Shire Deal Is DOA

    Allergan plc (NYSE: AGN ) stock was volatile Thursday after CNBC reported the firm will not pursue a Shire PLC (ADR) (NASDAQ: SHPG ) takeover, citing sources.  The Irish pharmaceutical had published a ...

  • Allergan Weighing Shire Bid Has Investors Worried About Deja Vu
    Bloomberg15 hours ago

    Allergan Weighing Shire Bid Has Investors Worried About Deja Vu

    Allergan Plc investors have been waiting for the drugmaker to make a bold move after the shares took a beating over the past year, but a potential bid for Shire Plc may not be the deal they wanted.

  • M&A Shouldn't Be This Easy
    Bloomberg17 hours ago

    M&A Shouldn't Be This Easy

    London-listed drugmaker Shire Plc has nudged Japan's Takeda Pharmaceutical Co. to up its takeover proposal twice to 44 billion pounds ($62.5 billion). Allergan Plc said on Thursday it was considering a bid only to say it wouldn’t after its shares suffered a bad reaction. Takeda must have thought it was dangling a knockout price for Shire.

  • Reuters17 hours ago

    Exclusive - Allergan in talks to acquire Shire, competing against Takeda: sources

    It is not clear whether Allergan has submitted an offer, and there is no certainty of a bid, the sources said. Shire on Thursday said it had rejected an offer worth around $61 billion from Takeda. Allergan declined to comment, while Shire and Allergan did not immediately respond to requests for comment.

  • Market Realist17 hours ago

    No Bid Coming for Shire Reportedly

    CNBC saying no bid is likely.  Allergan is off its lows – only down $5 now and Shire is back to flat after being up as much as $15 (~10%) earlier.

  • Benzinga17 hours ago

    Allergan Confirms Consideration Of Shire Bid

    Allergan plc (NYSE: AGN ) confirmed in a mid-morning statement Thursday that it was considering a bid for Shire PLC (ADR) (NASDAQ: SHPG ) but has not extended an official offer. “There can be no certainty ...

  • MarketWatch18 hours ago

    Allergan shares plummet 6% on Shire bid interest, while Shire surges 8%

    Allergan PLC shares plummeted 6% in heavy morning trade after the company confirmed it was in the "early stages" of a potential bid for Shire PLC , though no offer has been made. In doing so, ...

  • Allergan will not bid for Shire, sources tell CNBC
    CNBC Videos16 hours ago

    Allergan will not bid for Shire, sources tell CNBC

    CNBC’s David Faber reports that pharma company Allergan will not follow through with a big on Shire, according to sources.